Methodology

How market entry is assessed.

01

Why a structured framework

Vantro evaluates each market across six structured dimensions, rating each as Ready, Moderate, or Complex based on verified data from regulatory authorities, WHO, and the World Bank. Every rating is traceable to a source, calibrated to your product type and existing clearances.

02

The six dimensions

Each market is assessed across six dimensions. Every dimension is rated Ready, Moderate, or Complex — no composite scores, no weighted averages. The rating is calibrated to the specific product type and existing regulatory clearances the user provides.

Ready
Favourable conditions — low friction for this dimension
Moderate
Manageable barriers — additional planning required
Complex
Significant friction — high regulatory or operational barriers
01

Regulatory Pathway

What it measures
The specific approval route available given the user's existing clearances — whether a reliance pathway exists, which national authority registers the product, and what technical documentation is required. For a product with CE Mark, the assessment identifies whether the target authority accepts CE documentation as the basis for a local dossier (reliance) or requires an independent full submission.
Why it matters for entry decisions
Regulatory complexity is the single biggest variable in entry timeline and cost. A reliance pathway can cut registration time by 60–70% versus a full dossier submission. Understanding whether precedent exists at the authority — and for this product class specifically — is the first determination a market access team needs to make before committing resources to a market.
Data sources
National regulatory authority guidance documents and registration procedure publications: SFDA (Saudi Arabia), MOHAP/DHA (UAE), CDSCO (India), DAV/MOH (Vietnam), BPOM (Indonesia), FDA Philippines, PPB (Kenya), NAFDAC (Nigeria), SAHPRA (South Africa), EGDA (Egypt), TITCK (Turkey), and others. Supplemented by WHO prequalification pathway data and practitioner-verified submission experience.
Status definitions
ReadyReliance pathway available and authority has recent precedent for this product class. Foreign clearances (CE Mark, FDA 510k) accepted as primary basis for local dossier.
ModerateFull dossier required but the process is established and timelines are predictable. Authority has reviewed this product category before and requirements are clearly documented.
ComplexFull dossier required with long review history, authority capacity constraints, or no established precedent for this product category. High uncertainty in requirements or review outcome.
02

Timeline

What it measures
Realistic months from first submission to commercial clearance — including known bottlenecks, authority backlog data, and distributor onboarding lead time. Not the official stated timeline: the actual one. Vantro timeline estimates are drawn from practitioner experience and tracked review durations, not authority-published targets which frequently understate real processing time.
Why it matters for entry decisions
Timeline drives capital allocation, partner negotiations, and launch sequencing decisions. A market with a fast regulatory pathway but slow distributor onboarding is still a long market. Getting timeline wrong leads to misallocated resource and delayed revenue. Timeline is assessed end-to-end: from initial submission to first commercial sale, including all dependencies.
Data sources
Practitioner-tracked review durations for each authority, cross-referenced against WHO prequalification processing statistics and publicly available authority performance reports where available. Distributor onboarding estimates derived from in-market practitioner experience. Backlog data from authority public notices and practitioner network.
Status definitions
ReadyUnder 12 months end-to-end, including distributor onboarding. Process is well-defined and authority review times are consistent.
Moderate12–18 months. Process is established but review backlog, documentation requirements, or onboarding lead time extends the path to first commercial sale.
Complex18+ months, or high variance — timeline is unpredictable due to authority backlog, capacity constraints, political factors, or significant process uncertainty.
03

Procurement Structure

What it measures
How health products are purchased in this market: public/private split, tender cycle cadence, formulary listing requirements, and which donor channels are active and relevant for the specific product category. Donor channel relevance is product-type specific — vaccines surface GAVI/UNICEF context, diagnostics surface PEPFAR/Global Fund context, consumer health products surface neither.
Why it matters for entry decisions
Procurement structure determines the commercial model. A market with 80% public procurement requires a tender strategy, formulary relationships, and patience for cycle timing. One with 80% private channel requires distributor relationships and commercial pricing strategy. Misreading procurement structure is one of the most common reasons market entry planning fails — products get registered but cannot reach volume because the wrong channel was prioritised.
Data sources
WHO Global Health Observatory health system financing data, World Bank healthcare expenditure data, UNICEF Supply Division procurement volumes, Global Fund country programme data, GAVI procurement and co-financing structures, USAID country health programme spend. Supplemented by national health authority procurement regulations and tender cycle publications.
Status definitions
ReadyAccessible procurement with clear entry points in both public and private channels. Tender process is established, cycles are predictable, and private channel is commercially viable without tender dependency.
ModerateProcurement accessible but requires tender registration, formulary listing, or distributor pre-qualification before volume is achievable. Entry is possible but requires structured preparation.
ComplexDominant public channel with long tender cycles, opaque procurement processes, significant formulary barriers, or limited private sector alternative that can support commercial viability.
04

Pricing & Reimbursement

What it measures
Whether the Ministry of Health sets reference or ceiling prices, what commercial pricing flexibility exists, and whether reimbursement listing is required for meaningful market access. Assessed against the specific product category — price controls on pharmaceuticals differ from those on medical devices, and IVD pricing dynamics differ from both.
Why it matters for entry decisions
Mandatory price ceilings compress margins and can make a market commercially unviable despite accessible regulatory and procurement pathways. Reimbursement listing requirements add time and process burden beyond registration. Understanding pricing constraints before market entry avoids the common trap of successfully registering a product that cannot be priced commercially — a scenario that consumes significant resource without generating revenue.
Data sources
Ministry of Health tariff schedules and pharmaceutical price control regulations. National insurance authority reimbursement lists and pricing submissions procedures. World Bank healthcare expenditure per capita data for commercial pricing context. NPPA (India), NMPB (Nigeria), SFDA tariff schedules (Saudi Arabia), and equivalent national pricing authorities.
Status definitions
ReadyCommercial pricing flexibility with no mandatory ceiling. Reimbursement not required for meaningful market access — products can be distributed and sold without listing.
ModerateReference pricing in force but negotiable, or reimbursement listing recommended but not required. Pricing is constrained but commercial viability is achievable with appropriate positioning.
ComplexMandatory ceiling prices, full MoH price approval required before commercial distribution, or reimbursement listing essential for any significant volume. Margin is structurally compressed.
05

Local Partner Requirements

What it measures
Whether a local entity or distributor is legally required for registration or market entry, what entity type rules apply (local ownership requirements, percentage thresholds), and typical onboarding lead time for a compliant local partner. Assessed based on direct regulatory authority guidance and current market practice.
Why it matters for entry decisions
Mandatory local partner requirements add cost, time, and execution risk. Finding and qualifying a compliant local partner can take 6–18 months in complex markets. For companies without existing in-country relationships, this is often the longest and most uncertain part of the entry process — and the most underestimated. Selecting the wrong partner in a mandatory-partner market is costly to unwind and can delay market access by years.
Data sources
National regulatory authority registration procedures specifying local agent or distributor requirements. Foreign investment and entity ownership regulations from national commerce ministries. Practitioner-verified market practice for partner onboarding lead times in each covered market.
Status definitions
ReadyLocal partner recommended but not legally required for registration or distribution. Foreign entity can register and distribute directly, or appoint a partner as a commercial decision rather than a legal requirement.
ModerateLocal distributor required for registration but options are available and onboarding is straightforward. The partner market is established and qualified candidates exist.
ComplexMandatory local entity with ownership rules, significant onboarding lead time, or a limited pool of qualified partners. Finding and qualifying a compliant partner is a material constraint on entry timeline.
06

Tax & Customs Exposure

What it measures
Import duty rates, VAT/GST, medical device exemptions, and landed cost impact on margin and competitive pricing.
Why it matters
High effective duty and tax rates directly reduce margin and can make imported products uncompetitive against locally manufactured alternatives. For low-margin categories, landed cost analysis is often the deciding factor in go/no-go.
Data sources
National customs authority tariff schedules, HS code classification guidance, VAT and GST regulations, medical device and pharmaceutical exemption schedules per market.
Status definitions
Ready0% or low duty, clear exemptions, straightforward customs clearance.
ModerateModerate duties or VAT with partial exemptions. Clearance predictable but adds cost.
ComplexHigh effective rates, HS classification risk, or lengthy customs clearance adding meaningful cost and time.
03

Data sources and verification

Vantro draws on three primary source categories. All data points are source-cited and carry a last-verified date. Timeline estimates reflect actual review durations based on practitioner experience — not official stated targets, which frequently understate real processing time.

National Regulatory Authorities
→Direct regulatory guidance documents, registration requirements, and fee schedules from 20+ national authorities
→Includes: SFDA/NUPCO (Saudi Arabia), MOHAP/DHA (UAE), CDSCO/FSSAI (India), DAV/MOH (Vietnam), BPOM (Indonesia), FDA Philippines/DOH, PPB/KEBS (Kenya), NAFDAC (Nigeria), SAHPRA (South Africa), EGDA/MOH (Egypt), FDB (Ghana), EFDA (Ethiopia)
→Supplemented by WHO prequalification pathway data and national pharmacopoeia publications where relevant
Multilateral Databases
→WHO Global Health Observatory — health system indicators, UHC coverage, disease burden, health financing data
→World Bank Open Data — GDP per capita, healthcare expenditure as % of GDP, ease of doing business, trade logistics data
→UNICEF Supply Division — procurement volumes, product categories, supplier lists, and pricing benchmarks
→UNDP Human Development Reports — market context and development indicators
→UNCTAD TRAINS — tariff and trade barrier data for customs and duty analysis
Donor Procurement Data
→Global Fund — country programme procurement data, eligibility criteria, and active product categories by market
→GAVI — vaccine procurement structures, co-financing models, and country eligibility
→USAID — country health programme spend, procurement channels, and implementing partner data
Practitioner Knowledge
→Timeline estimates reflect actual review durations tracked by practitioners with direct experience in these markets — not authority-published targets
→Procurement structure data, tender cycle timing, and local partner requirement details verified by global health market access practitioners with experience at WHO, UNICEF, World Bank, Bloomberg Philanthropies, and GIZ across 20+ LMICs
→Published in BMJ Global Health, The Lancet, and BMJ Innovations — practitioner credentials are verifiable
Update Frequency
MarketsVerification cadence
Priority markets — Saudi Arabia, UAE, India, Vietnam, PhilippinesQuarterly verification
Secondary markets — Indonesia, Kenya, South Africa, Nigeria, Egypt, Ghana, EthiopiaSemi-annual verification
All marketsImmediate update on confirmed regulatory change
Last full verificationFebruary 2026
04

Scope and limitations

Vantro analysis is directional. A status rating reflects conditions as of the last verification date shown. Regulatory environments change — sometimes quickly, following elections, policy changes, or authority reorganisations. A rating that was accurate at the time of verification may not reflect subsequent changes.

Vantro dimension ratings are appropriate for: market prioritisation decisions, resource allocation across market entry programmes, investment committee presentations, and first-pass feasibility assessment. They are not appropriate for use as the sole basis for formal regulatory submissions, legal compliance assessments, or go-to-market execution without local expert validation.

Important

For formal market entry decisions, engage qualified local regulatory counsel in the target market. Regulatory requirements, timelines, and procurement conditions vary significantly at the country level and change over time. Vantro ratings provide structured directional intelligence — not a definitive compliance assessment.

Vantro is not a regulatory consultancy and does not advise on specific submissions, dossier preparation, authority engagement strategy, or local partner selection.

Users should treat Vantro dimension ratings as a starting point for market prioritisation and planning. Decisions with significant capital or strategic consequences should always be validated by in-country experts with current, direct experience in the relevant authority and product category.